Protein subunit vaccine containing receptor binding domain (RBD) of SARS-CoV-2 virus produced through well-established platform (which is used for the production of vaccines like Hepatitis B).

Contains CpG1018 and aluminium hydroxide as adjuvants which enhances both antibody and cellular immune responses against SARS-CoV-2 virus.

4 Clinical trials involving 4392 volunteer subjects of age group 5 to 80 years from >35 study centres across India to demonstrate the safety and immunogenicity.

Significantly higher neutralizing antibody titres compared to Covishield for both Wuhan and Delta variants. Robust antibody and cellular immune response.

Long term follow-up (≥ 6months) data shows high persistence of neutralizing antibody titres.

Neutralizing antibodies demonstrated against Delta, Beta and Omicron variants

Excellent safety profile; No severe grades or serious adverse events. No adverse events of special interest on long term monitoring. Mild to moderate adverse events were almost 50% less than the comparator Covid-19 vaccine.

Neutralizing antibody titers and clinical trial experience indicates high vaccine effectiveness in preventing symptomatic infection and severe disease; >90% vaccine effectiveness against Wuhan variant and >80% vaccine effectiveness against Delta variant based on neutralizing antibodies correlates of protection from Covid-19 vaccine trial analysis.